We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is a Beat in Store for Epizyme (EPZM) This Earnings Season?
Read MoreHide Full Article
Epizyme, Inc. is expected to report first-quarter 2018 results on May 8, before the market opens.
In the last reported quarter, the company delivered a positive earnings surprise of 7.14%. In fact, its track record has been solid, with Epizyme surpassing expectations in each of the trailing four quarters, recording an average positive earnings surprise of 8.91%.
Epizyme’s shares have returned 10% year to date as against the industry’s decline of 12.1%.
Let’s see how things are shaping up for this quarter.
What Does the Zacks Model Unveil?
Our proven model shows that Epizyme is likely to beat on earnings in the to-be-reported quarter because it has the right combination of two key ingredients — a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) — which have a significantly higher chance of beating estimates.
Zacks ESP: Epizyme has an Earnings ESP of +0.18% as both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at a loss of 54 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Note that Sell-rated stocks (Zacks Rank #4 or 5) should never be considered going into an earnings announcement.
Let’s see how things are shaping up for this announcement.
Factors Influencing This Quarter
Epizyme has made significant progress with its lead candidate, tazemetostat (an EZH2 inhibitor), for the treatment of multiple types of hematological malignancies and genetically defined solid tumors.
Epizyme is conducting a broad clinical development program for tazemetostat as both a monotherapy and combination treatment in relapsed/refractory and first-line non-Hodgkin lymphoma (“NHL”). The company expects to submit a new drug application (“NDA”) for the NHL in 2019.
Epizyme has identified a path to submit for accelerated approval for tazemetostat for the treatment of patients with epithelioid sarcoma after discussions with the FDA in 2017. The company expects to file its first NDA seeking accelerated approval of tazemetostat for epithelioid sarcoma in the fourth quarter of 2018.
The company is also exploring tazemetostat to increase the clinical activity of immuno-oncology therapies by combining an anti-PD 1 or PDL-1 agent. Under its collaboration with Roche (RHHBY - Free Report) , the company is evaluating tazemetostat, in combination with anti-PD-L1 cancer immunotherapy, Tecentriq, for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (“DLBCL”) to determine the recommended phase II dose and advance the study.
Epizyme plans to complete enrollment of patients with relapsed or refractory DLBCL with an EZH2 mutation in its ongoing phase II study of tazemetostat as a monotherapy in 2018; The company expects to present updated monotherapy data and announce next steps for the program in mid-to-second half of 2018.
Epizyme plans to complete investigational new drug enabling studies for EZM8266, its G9a inhibitor designed to treat patients with sickle cell disease, in 2018 and prepare for a phase 1 study in early 2019.
Stocks to Consider
Here are some health care stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Adverum Biotechnologies, Inc. (ADVM - Free Report) has an Earnings ESP of +6.9% and currently carries a Zacks Rank #3. The company is expected to release first-quarter results on May 8.
Keryx Biopharmaceuticals, Inc. has an Earnings ESP of +11.69% and currently carries a Zacks Rank #3. The company is expected to release first-quarter results this month.
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Is a Beat in Store for Epizyme (EPZM) This Earnings Season?
Epizyme, Inc. is expected to report first-quarter 2018 results on May 8, before the market opens.
In the last reported quarter, the company delivered a positive earnings surprise of 7.14%. In fact, its track record has been solid, with Epizyme surpassing expectations in each of the trailing four quarters, recording an average positive earnings surprise of 8.91%.
Epizyme’s shares have returned 10% year to date as against the industry’s decline of 12.1%.
Let’s see how things are shaping up for this quarter.
What Does the Zacks Model Unveil?
Our proven model shows that Epizyme is likely to beat on earnings in the to-be-reported quarter because it has the right combination of two key ingredients — a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) — which have a significantly higher chance of beating estimates.
Zacks ESP: Epizyme has an Earnings ESP of +0.18% as both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at a loss of 54 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Epizyme’s Zacks Rank #3, when combined with a positive ESP makes us reasonably confident of an earnings beat. You can see the complete list of today’s Zacks #1 Rank stocks here.
Note that Sell-rated stocks (Zacks Rank #4 or 5) should never be considered going into an earnings announcement.
Let’s see how things are shaping up for this announcement.
Factors Influencing This Quarter
Epizyme has made significant progress with its lead candidate, tazemetostat (an EZH2 inhibitor), for the treatment of multiple types of hematological malignancies and genetically defined solid tumors.
Epizyme is conducting a broad clinical development program for tazemetostat as both a monotherapy and combination treatment in relapsed/refractory and first-line non-Hodgkin lymphoma (“NHL”). The company expects to submit a new drug application (“NDA”) for the NHL in 2019.
Epizyme has identified a path to submit for accelerated approval for tazemetostat for the treatment of patients with epithelioid sarcoma after discussions with the FDA in 2017. The company expects to file its first NDA seeking accelerated approval of tazemetostat for epithelioid sarcoma in the fourth quarter of 2018.
The company is also exploring tazemetostat to increase the clinical activity of immuno-oncology therapies by combining an anti-PD 1 or PDL-1 agent. Under its collaboration with Roche (RHHBY - Free Report) , the company is evaluating tazemetostat, in combination with anti-PD-L1 cancer immunotherapy, Tecentriq, for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (“DLBCL”) to determine the recommended phase II dose and advance the study.
Epizyme plans to complete enrollment of patients with relapsed or refractory DLBCL with an EZH2 mutation in its ongoing phase II study of tazemetostat as a monotherapy in 2018; The company expects to present updated monotherapy data and announce next steps for the program in mid-to-second half of 2018.
Epizyme plans to complete investigational new drug enabling studies for EZM8266, its G9a inhibitor designed to treat patients with sickle cell disease, in 2018 and prepare for a phase 1 study in early 2019.
Stocks to Consider
Here are some health care stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Adverum Biotechnologies, Inc. (ADVM - Free Report) has an Earnings ESP of +6.9% and currently carries a Zacks Rank #3. The company is expected to release first-quarter results on May 8.
Keryx Biopharmaceuticals, Inc. has an Earnings ESP of +11.69% and currently carries a Zacks Rank #3. The company is expected to release first-quarter results this month.
Epizyme, Inc. Price and EPS Surprise
Epizyme, Inc. Price and EPS Surprise | Epizyme, Inc. Quote
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>